- Home
- SFL vs SDGR Comparison
SFL vs SDGR Comparison
Compare SFL & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SFL | SDGR |
|---|---|---|
| Founded | 2003 | 1990 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SFL | SDGR |
|---|---|---|
| Price | $8.05 | $18.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | $11.00 | ★ $26.25 |
| AVG Volume (30 Days) | ★ 1.2M | 822.8K |
| Earning Date | 02-11-2026 | 02-25-2026 |
| Dividend Yield | ★ 13.67% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $774,521,000.00 | $256,951,000.00 |
| Revenue This Year | N/A | $23.69 |
| Revenue Next Year | N/A | $20.46 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 32.90 |
| 52 Week Low | $6.73 | $15.99 |
| 52 Week High | $11.14 | $28.47 |
Technical Indicators
Market Signals| Indicator | SFL | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 58.35 | 56.97 |
| Support Level | $7.66 | $17.50 |
| Resistance Level | $7.84 | $19.44 |
| Average True Range (ATR) | 0.18 | 0.72 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 78.71 | 70.20 |
Price Performance
Historical ComparisonAbout SFL SFL Corporation Ltd
SFL Corp Ltd is an international ship-owning and chartering company. The company is engaged in transporting crude oil and oil products, dry bulk and containerized cargoes, freight of rolling cargo, and offshore drilling and related activities.
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.